drugset / Trial / NCT00525668

Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)

NCT00525668

Phase 1/2 Completed 120 enrolled Charite University, Berlin, Germany
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Hypothesis: Sunphenon, a green tea extract containing 95% egcg, given daily as oral medication over a period of 18 months has anti-inflammatory and neuroprotective properties in patients with relapsing-remitting multiple sclerosis as assessed by magnetic resonance imaging and clinical examination (EDSS and MSFC).

Timeline

Start
2007-09
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator epigallocatechin-3-gallate Unknown 400 mg Oral